How This Evidence Evolved
Lung Cancer Sublobar Resection
Challenging Lobectomy as the Standard of Care for Small Peripheral Non-Small Cell Lung Cancer
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
5-year overall survival — segmentectomy 94.3% vs lobectomy 91.1% (noninferiority and superiority confirmed)
Disease-free survival — sublobar resection noninferior to lobectomy at median 7-year follow-up
Follow-up studies, subgroup analyses, and real-world validation
Current standard of care and ongoing research directions
Landmark Trials in This Story
Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group
Local recurrence: limited resection 3-fold higher than lobectomy (P=.008)
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
5-year overall survival — segmentectomy 94.3% vs lobectomy 91.1% (noninferiority and superiority confirmed)
Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer
Disease-free survival — sublobar resection noninferior to lobectomy at median 7-year follow-up
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.